Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Fate Therapeutics reported Q1 2026 financial results and business updates, highlighting the planned initiation of the Phase 2 RECLAIM-LN trial of FT819 in lupus nephritis patients in H2 2026. The FDA selected FT819 into the CDRP program to accelerate development, and the company presented positive clinical and preclinical data for FT819 and FT839 a…